Citius Oncology, Inc. (CTOR)
NASDAQ:CTOR
Want to see CTOR full AI Analyst Report?
Total Valuation
Citius Oncology has a market cap or net worth of $75.92M. The enterprise value is $72.42M.
Market Cap$75.92M
Enterprise Value$72.42M
Share Statistics
Citius Oncology has 88,275,210 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding88,275,210
Owned by Insiders6.93%
Owned by Institutions6.46%
Financial Efficiency
Citius Oncology’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -45.72%.
Return on Equity (ROE)-0.55
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-45.72%
Return on Capital Employed (ROCE)-0.46
Revenue Per Employee0.00
Profits Per Employee-86.88K
Employee Count285
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Citius Oncology is ―. Citius Oncology’s PEG ratio is -0.45.
PE Ratio―
PS Ratio0.00
PB Ratio3.32
Price to Fair Value3.32
Price to FCF-27.08
Price to Operating Cash Flow-5.97
PEG Ratio-0.45
Income Statement
In the last 12 months, Citius Oncology had revenue of 0.00 and earned -24.76M in profits. Earnings per share was -0.34.
Revenue0.00
Gross Profit0.00
Operating Income-23.52M
Pretax Income-23.70M
Net Income-24.76M
EBITDA-23.49M
Earnings Per Share (EPS)-0.34
Cash Flow
In the last 12 months, operating cash flow was -12.89M and capital expenditures -9.00, giving a free cash flow of -12.89M billion.
Operating Cash Flow-12.89M
Free Cash Flow-12.89M
Free Cash Flow per Share-0.15
Dividends & Yields
Citius Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.32
52-Week Price Change-1.24%
50-Day Moving Average0.89
200-Day Moving Average1.48
Relative Strength Index (RSI)61.75
Average Volume (3m)203.68K
Important Dates
Citius Oncology upcoming earnings date is May 20, 2026, After Close (Not Confirmed).
Last Earnings DateFeb 13, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Citius Oncology as a current ratio of 0.56, with Debt / Equity ratio of 6.51%
Current Ratio0.56
Quick Ratio0.11
Debt to Market Cap0.03
Net Debt to EBITDA<0.01
Interest Coverage Ratio-107.89
Taxes
In the past 12 months, Citius Oncology has paid 1.06M in taxes.
Income Tax1.06M
Effective Tax Rate-0.04
Enterprise Valuation
Citius Oncology EV to EBITDA ratio is -6.33, with an EV/FCF ratio of -27.06.
EV to Sales0.00
EV to EBITDA-6.33
EV to Free Cash Flow-27.06
EV to Operating Cash Flow-27.06
Balance Sheet
Citius Oncology has $7.30M in cash and marketable securities with $3.80M in debt, giving a net cash position of $3.50M billion.
Cash & Marketable Securities$7.30M
Total Debt$3.80M
Net Cash$3.50M
Net Cash Per Share$0.04
Tangible Book Value Per Share$0.61
Margins
Gross margin is 79.99%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin79.99%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Citius Oncology is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside460.75% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―